Lenacapavir HIV Prevention: Gilead’s Stra...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly inject...
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
10-Year Health Plan: Transforming England’s NHS for the Future
The Value of Self-Care in Public Health: Insights and Implications for Europe
Impending Net Drug Price Transparency Regulation in the U.S.
How Does Mind’s AI-Driven Mental Healthcare Transform Care?
DALY Modeling Methods for Enhanced Health Economics and Policy Analysis
Pharmaceutical Pricing Issues: Beyond Overpricing and Profit Motives
FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Pr...
Canada Launches Consultation for Essential Prescription Drugs List
NICE Rejects Donanemab: Treatment Cost-Effectiveness
PCV20 Reimbursement Guidelines: Analysis of Dutch Advisory Council Recommenda...
NICE Approves Transformative Multiple Myeloma Treatment